Developer docs
API playgroundTry for free, no card

Search company profiles

EOFlow

Full company profile

uuid00052m9

Namestring
EOFlow
Legal namestring
EOFlow Co. Ltd.
Websiteurl
eoflow.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

EOFlow Co. Ltd. is a South Korea-based medical device company headquartered in Seongnam that develops the EOPatch, a tubeless patch pump-based automated insulin delivery system for diabetes patients requiring continuous subcutaneous insulin infusion. The company competes directly with Insulet's Omnipod platform by offering a miniaturized, wearable form factor that eliminates the tubing of conventional insulin pumps. EOFlow operates with 51-100 employees, was founded in 2011, and trades on KOSDAQ under ticker 294090.

EOFlow's revenue model is anchored in the sale and recurring consumables of a single product line (EOPatch), targeting diabetes patients as the primary end-user persona; no distribution channels, pricing details, or named enterprise customers are publicly disclosed. The company has raised approximately $28 million across disclosed funding rounds between 2015 and 2019, led by LB Investment, and was the subject of a ~$738 million Medtronic acquisition attempt that was called off in December 2023. In parallel, EOFlow defended a multi-year trade secret dispute with Insulet in which a $452 million verdict was reduced to $60 million and ultimately overturned by the U.S. Court of Appeals for the Federal Circuit on May 29, 2026, eliminating that litigation overhang.

The commercial trajectory is constrained by single-product exposure, an absence of disclosed distribution partnerships following the collapse of the Medtronic deal, and no visible product roadmap beyond the EOPatch. Leadership comprises founder and CEO Jesse J. Kim, president Luis Malave, and chief compliance officer Ian Welsford, oriented around regulatory and compliance execution rather than scale commercialization.

Short descriptiontext

EOFlow is a South Korea-based medical device company that develops the EOPatch, a tubeless patch pump for automated insulin delivery, serving diabetes patients who require continuous subcutaneous insulin infusion.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
wearable insulin pumps, patch pump technology, automated insulin delivery, diabetes management devices, tubeless insulin pump
Industry3 codes
PRIMARYHLAHAHAC
Patch Pumps & Wearable Insulin Delivery
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAIAG
Insulin Pumps & Patch Pumps
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Diabetes Management Devices
Social media profiles3 records
Cost components6 values
Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1EOPatch
Description

Automated insulin delivery system using patch pump technology developed by EOFlow

drugdeliverybusiness.com
Core offering1 text field

EOFlow develops and manufactures the EOPatch, a tubeless, wearable patch pump-based automated insulin delivery system for continuous subcutaneous insulin infusion (CSII) in diabetes management. The EOPatch is positioned as a direct competitor to Insulet's Omnipod platform in the wearable insulin delivery market, with miniaturization of the patch pump form factor as its primary technical differentiator.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

EOFlow offers a single unified product: the EOPatch, a tubeless patch pump-based automated insulin delivery system designed for people with diabetes. The EOPatch represents EOFlow's core technology focus in the wearable insulin delivery market.

Product and service1 record
1EOPatch
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Insulet manufactures the Omnipod tubeless patch pump for automated insulin delivery, the closest direct competitor to EOFlow's EOPatch. Both target the same diabetes patient population seeking tubeless CSII therapy with similar form-factor and use-case propositions.

TypeBroad incumbent
Description

Medtronic operates the MiniMed insulin pump and broader diabetes management portfolio and attempted to acquire EOFlow for ~$738M in 2023. It is a broad incumbent in diabetes devices that would integrate EOFlow's patch-pump technology into a wider portfolio including CGMs and integrated AID systems.

TypeDirect peer
Description

Tandem markets the t:slim X2 insulin pump and the Tandem Mobi tubeless pump alongside AID algorithms. It is a direct peer in the automated insulin delivery category, competing for the same Type 1 diabetes patient population with comparable pump-based therapy offerings.

TypeDirect peer
Description

Ypsomed manufactures the mylife YpsoPump and is developing its own tubeless patch pump (mylife Loop) for the AID market. It is a direct competitor in patch-pump and automated insulin delivery, particularly active in European and partner-ecosystem channels.

TypeRegional player
Description

Sooil is a Korean manufacturer of the Dana Diabecare insulin pumps and a fellow South Korean competitor to EOFlow. It is a regional peer with overlapping patch/tubed pump offerings but primarily serving the domestic Korean and selected Asian markets.

TypeBroad incumbent
Description

Roche operates the Accu-Chek insulin pump and broader diabetes care portfolio within its large diagnostics franchise. It is a broad incumbent offering insulin delivery as part of a wider diabetes management and BGM ecosystem overlapping with EOFlow's addressable market.

TypeOthers
Description

Dexcom is the leading continuous glucose monitor (CGM) manufacturer and a key integration partner for automated insulin delivery systems. It is an ecosystem participant rather than direct competitor, but its CGM data is essential to AID systems like EOPatch.

TypeBroad incumbent
Description

Abbott manufactures the FreeStyle Libre CGM and is expanding into integrated diabetes management. As a broad incumbent with a dominant CGM franchise, it is a key ecosystem participant for AID systems including EOPatch.

9Terumo Corporation
TypeBroad incumbent
Description

Terumo has historically participated in insulin patch-pump development (formerly partnering with Dexcom on TypeZero) and operates a broader medical device portfolio. It is a broad incumbent with prior strategic interest in the patch-pump AID category overlapping with EOFlow's product space.

TypeEmerging player
Description

Beta Bionics developed the iLet bionic pancreas, an automated insulin dosing system competing in the AID category. As a smaller, focused entrant, it represents an emerging peer pursuing the same automated insulin delivery opportunity as EOFlow's EOPatch.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EOFlow

Diabetes Management Deviceseoflow.com

EOFlow is a South Korea-based medical device company that develops the EOPatch, a tubeless patch pump for automated insulin delivery, serving diabetes patients who require continuous subcutaneous insulin infusion.

What EOFlow does

EOFlow Co. Ltd. is a South Korea-based medical device company headquartered in Seongnam that develops the EOPatch, a tubeless patch pump-based automated insulin delivery system for diabetes patients requiring continuous subcutaneous insulin infusion. The company competes directly with Insulet's Omnipod platform by offering a miniaturized, wearable form factor that eliminates the tubing of conventional insulin pumps. EOFlow operates with 51-100 employees, was founded in 2011, and trades on KOSDAQ under ticker 294090.

EOFlow's revenue model is anchored in the sale and recurring consumables of a single product line (EOPatch), targeting diabetes patients as the primary end-user persona; no distribution channels, pricing details, or named enterprise customers are publicly disclosed. The company has raised approximately $28 million across disclosed funding rounds between 2015 and 2019, led by LB Investment, and was the subject of a ~$738 million Medtronic acquisition attempt that was called off in December 2023. In parallel, EOFlow defended a multi-year trade secret dispute with Insulet in which a $452 million verdict was reduced to $60 million and ultimately overturned by the U.S. Court of Appeals for the Federal Circuit on May 29, 2026, eliminating that litigation overhang.

The commercial trajectory is constrained by single-product exposure, an absence of disclosed distribution partnerships following the collapse of the Medtronic deal, and no visible product roadmap beyond the EOPatch. Leadership comprises founder and CEO Jesse J. Kim, president Luis Malave, and chief compliance officer Ian Welsford, oriented around regulatory and compliance execution rather than scale commercialization.

EOFlow firmographics

Firmographics
Name
EOFlow
Legal name
EOFlow Co. Ltd.
Website
https://eoflow.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
EOFlow is a South Korea-based medical device company that develops the EOPatch, a tubeless patch pump for automated insulin delivery, serving diabetes patients who require continuous subcutaneous insulin infusion.
Ownership category
akta.pro rank

EOFlow industry classification

Industry
Product category
Diabetes Management Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAHAC
Patch Pumps & Wearable Insulin Delivery
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAIAG
Insulin Pumps & Patch Pumps
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Wearable insulin pumps
  • Patch pump technology
  • Automated insulin delivery
  • Diabetes management devices
  • Tubeless insulin pump

Where EOFlow is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Markets served

EOFlow business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Others

EOFlow product offering

Product offering

Core offering

EOFlow develops and manufactures the EOPatch, a tubeless, wearable patch pump-based automated insulin delivery system for continuous subcutaneous insulin infusion (CSII) in diabetes management. The EOPatch is positioned as a direct competitor to Insulet's Omnipod platform in the wearable insulin delivery market, with miniaturization of the patch pump form factor as its primary technical differentiator.

Product overview

EOFlow offers a single unified product: the EOPatch, a tubeless patch pump-based automated insulin delivery system designed for people with diabetes. The EOPatch represents EOFlow's core technology focus in the wearable insulin delivery market.

Differentiator

Problem solved

Functional benefit

Brands

  • EOPatch: Automated insulin delivery system using patch pump technology developed by EOFlow

Products and services

  • EOPatch

Companies that use EOFlow

Customer profile

Segments1 record

Ideal customer profiles1 record

EOFlow technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

EOFlow partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights3 records

EOFlow competitors and assessment

Company assessment

Direct peers

  • Insulet Corporation: Insulet manufactures the Omnipod tubeless patch pump for automated insulin delivery, the closest direct competitor to EOFlow's EOPatch. Both target the same diabetes patient population seeking tubeless CSII therapy with similar form-factor and use-case propositions.
  • Tandem Diabetes Care: Tandem markets the t:slim X2 insulin pump and the Tandem Mobi tubeless pump alongside AID algorithms. It is a direct peer in the automated insulin delivery category, competing for the same Type 1 diabetes patient population with comparable pump-based therapy offerings.
  • Ypsomed Holding AG: Ypsomed manufactures the mylife YpsoPump and is developing its own tubeless patch pump (mylife Loop) for the AID market. It is a direct competitor in patch-pump and automated insulin delivery, particularly active in European and partner-ecosystem channels.

Broad incumbents

  • Medtronic plc: Medtronic operates the MiniMed insulin pump and broader diabetes management portfolio and attempted to acquire EOFlow for ~$738M in 2023. It is a broad incumbent in diabetes devices that would integrate EOFlow's patch-pump technology into a wider portfolio including CGMs and integrated AID systems.
  • Roche Diabetes Care: Roche operates the Accu-Chek insulin pump and broader diabetes care portfolio within its large diagnostics franchise. It is a broad incumbent offering insulin delivery as part of a wider diabetes management and BGM ecosystem overlapping with EOFlow's addressable market.
  • Abbott Diabetes Care: Abbott manufactures the FreeStyle Libre CGM and is expanding into integrated diabetes management. As a broad incumbent with a dominant CGM franchise, it is a key ecosystem participant for AID systems including EOPatch.
  • Terumo Corporation: Terumo has historically participated in insulin patch-pump development (formerly partnering with Dexcom on TypeZero) and operates a broader medical device portfolio. It is a broad incumbent with prior strategic interest in the patch-pump AID category overlapping with EOFlow's product space.

Regional players

  • Sooil Development Co., Ltd. Sooil is a Korean manufacturer of the Dana Diabecare insulin pumps and a fellow South Korean competitor to EOFlow. It is a regional peer with overlapping patch/tubed pump offerings but primarily serving the domestic Korean and selected Asian markets.

Others

  • Dexcom, Inc. Dexcom is the leading continuous glucose monitor (CGM) manufacturer and a key integration partner for automated insulin delivery systems. It is an ecosystem participant rather than direct competitor, but its CGM data is essential to AID systems like EOPatch.

Emerging players

  • Beta Bionics: Beta Bionics developed the iLet bionic pancreas, an automated insulin dosing system competing in the AID category. As a smaller, focused entrant, it represents an emerging peer pursuing the same automated insulin delivery opportunity as EOFlow's EOPatch.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights5 records

Customer concentration

EOFlow social profiles

Digital presence

EOFlow financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EOFlow leadership team

Management profile

Number of profiles

Profiles3 records

EOFlow funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EOFlow M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EOFlow

What does EOFlow do?

EOFlow develops and manufactures the EOPatch, a tubeless, wearable patch pump-based automated insulin delivery system for continuous subcutaneous insulin infusion (CSII) in diabetes management. The EOPatch is positioned as a direct competitor to Insulet's Omnipod platform in the wearable insulin delivery market, with miniaturization of the patch pump form factor as its primary technical differentiator.

Is EOFlow a public or private company?

EOFlow is a private company. It is classified as public and is currently operating.

When was EOFlow founded?

EOFlow was founded in 2011. It employs 1 to 10 people.

Where is EOFlow based?

EOFlow is headquartered in Seongnam, South Korea, in the Asia region.

Who are EOFlow's main competitors?

Direct peers on record are Insulet Corporation, Tandem Diabetes Care and Ypsomed Holding AG. Broad incumbents are Medtronic plc, Roche Diabetes Care, Abbott Diabetes Care and Terumo Corporation. Sooil Development Co., Ltd. is listed as a regional player. Dexcom, Inc. is listed as an others. Beta Bionics is listed as an emerging player.

Does EOFlow have an API?

No public API is recorded for EOFlow.

What industry is EOFlow in?

EOFlow's product category is Diabetes Management Devices. Its primary akta.pro industry code is HLAHAHAC, Patch Pumps & Wearable Insulin Delivery, with a secondary code of HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Law360Insulet Can't Keep Injunction During Trade Secret AppealThe Federal Circuit denied Insulet Corp.'s request to keep an injunction against rival EOFlow Co. Ltd. while it appeals an axed $59 million trade secrets jury verdict to the U.S. Supreme Court. The denial means the injunction will not remain in place during the appeal.The future of tradingUS Appeals Court Denies Insulet Rehearing Requests in EOFlow Trade Secrets CaseThe US Federal Circuit denied Insulet's rehearing requests on October 19, 2026, in trade-secret and patent infringement litigation against EOFlow. The disclosed judgment amount was KRW 79.13 billion, equivalent to 82.68% of equity.Law360Full Fed. Circ. Won't Revive Insulet's $59M Trade Secrets WinThe Federal Circuit will not reinstate a jury's $59.4 million trade secret theft verdict against EOFlow Co. Ltd., rejecting Insulet Corp.'s request for rehearing of a panel decision overturning the award. The court's decision leaves the verdict in place.The future of tradingEOFlow restates 2024 audit opinion to unqualified from disclaimerEOFlow revised its fiscal 2024 audit opinion to unqualified from a disclaimer, citing a Sept. 29, 2026 filing. The company reported a consolidated net loss of KRW 91.88 billion on revenue of KRW 5.24 billion, with equity turning negative at KRW -22.43 billion from KRW 58.88 billion a year earlier.Law360Medtech Group Faults Fed. Circ. Trade Secret Timing RuleMedtech Group and a University of Texas law professor are urging the full Federal Circuit to revisit a decision that overturned Insulet Corp.'s trade secret victory against EOFlow Co. Ltd. The original ruling reversed a jury verdict that had been reduced to $59.4 million, citing that the lawsuit was filed untimely. This legal challenge highlights ongoing disputes over trade secret enforcement timing in the medical technology sector.Law360Insulet Urges Full Fed. Circ. To Revive $59M Trade Secret WinInsulet Corp. has petitioned the full Federal Circuit to review and reinstate a $59.4 million jury verdict for trade secret theft against EOFlow Co. Ltd., arguing that a split appellate panel's decision to overturn the award addressed a timeliness issue that neither party had raised. The medical device company, which develops insulin delivery products, is seeking to revive the damages after a three-judge panel reversed the verdict. This marks a significant appellate strategy by Insulet to recover what could be the largest trade secret damages awards in the medical device sector.JD SupraLatest Federal Court Cases: Insulet Corp. v. EOFlow, Co. Ltd.The Federal Circuit held it had jurisdiction over Insulet Corp. v. EOFlow, Co. Ltd., because patent claims were asserted, and the dismissal was with prejudice due to the statute of limitations. The court reversed the jury's $452 million trade secret damages award, finding the statute of limitations had run.DrugdeliverybusinessCourt overturns $60M win for Insulet in EOFlow trade secret spatThe U.S. Court of Appeals for the Federal Circuit overturned a $60 million verdict that had been awarded to Insulet in its trade secret dispute with EOFlow, ruling in favor of EOFlow. The court cited a three-year statute of limitations, finding that Insulet sued in 2023 despite alleging misappropriation beginning in 2018. Both companies develop automated insulin delivery systems using patch pump technology, with Insulet offering the Omnipod platform and EOFlow developing the EOPatch device.JonesdayTrade Secret Litigation Trends in Life Sciences | InsightsTrade secret litigation filings in life sciences have grown substantially since the 2016 Defend Trade Secrets Act, driven by heightened competition, increased M&A activity, and heightened awareness of IP value beyond patents. The article analyzes common dispute origins including employee mobility and collaboration agreements, and examines remedies such as significant damages awards and injunctive relief. Recent case studies including Insulet's $452M verdict against EOFlow (later reduced to $60M) and United Therapeutics' claims against Liquidia illustrate the substantial financial risks and strategic opportunities in trade secret protection for life sciences companies.